Biocon Biologics refinances USD 1.1 billion long-term debt through dollar bonds and a new syndicated facility, strengthening its capital structure and fueling long-term growth.
New Delhi, Oct 3 (PTI) Biocon Biologics on Thursday said it has refinanced USD 1.1 billion (Rs 9,347 crore) long-term debt through dollar bonds and new syndicated facility.
The company said the bonds will be issued by Biocon Biologics Global plc, a wholly owned subsidiary of the company, and will be backed by a strong security package, Biocon Biologics, a unit of Biocon Ltd, said in a statement.
The transaction is expected to settle on October 9, 2024 subject to customary closing conditions, it added.
"This strategic refinancing underscores our commitment to enhance financial flexibility, fuels Biocon Biologics' long-term growth and is core to the consolidation phase of our business," Biocon Biologics CEO and Managing Director Shreehas Tambe said.
The company expects the transaction to strengthen capital structure and allow it to redeploy investments into the business, including advancing our differentiated pipeline of biosimilars, he added.
"It will also enable us to diversify our investor base to include marquee global funds and healthcare investors who seek to participate in Biocon Biologics' growth story," Tambe said.
Shares of Biocon were trading 0.81 per cent down at Rs 367.40 apiece on BSE.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback